Alpha Spread
Search stocks here...
Sign Up Log in
Dashboard Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator
Pricing Investing Ideas
Alpha Spread
Dashboard Tools Investing Ideas Pricing About Us
Sign Up
Log in
Alpha Spread
Dashboard Tools Investing Ideas Pricing About Us
Sign Up
Log in
Amryt Pharma Holdings Ltd Logo

Amryt Pharma Holdings Ltd
LSE:AMYT

Watchlist Manager
Amryt Pharma Holdings Ltd Logo
Amryt Pharma Holdings Ltd
LSE:AMYT
Watchlist
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Dividends
Investor Relations
Discount Rate
Price: 143 GBX -11.73% Market Closed
Market Cap: 457.1m GBX
Activate Unlimited Plan
to continue AMYT research
Activate Unlimited Plan
to continue AMYT research

You've reached your weekly stock limit.

Sign Up
14-day money-back guarantee
Have any thoughts about
Amryt Pharma Holdings Ltd?
Write Note
Write Note Create Alert Ask AI
Add Note Why Create Notes?
Capture your thoughts
Note Buy Sell Hold Pass
US
Johnson & Johnson
NYSE:JNJ
Pharmaceuticals
US
Berkshire Hathaway Inc
NYSE:BRK.A
Financial Services
US
Bank of America Corp
NYSE:BAC
Banking
US
Mastercard Inc
NYSE:MA
Technology
US
UnitedHealth Group Inc
NYSE:UNH
Health Care
US
Exxon Mobil Corp
NYSE:XOM
Energy
US
Pfizer Inc
NYSE:PFE
Pharmaceuticals
US
Palantir Technologies Inc
NYSE:PLTR
Technology
US
Nike Inc
NYSE:NKE
Textiles, Apparel & Luxury Goods
US
Visa Inc
NYSE:V
Technology
CN
Alibaba Group Holding Ltd
NYSE:BABA
Retail
US
JPMorgan Chase & Co
NYSE:JPM
Banking
US
Coca-Cola Co
NYSE:KO
Beverages
US
Walmart Inc
NYSE:WMT
Retail
US
Verizon Communications Inc
NYSE:VZ
Telecommunication
US
Chevron Corp
NYSE:CVX
Energy


Add Price Alert
Price Target:
Last Price: 143 GBX

We'll email you a reminder when the closing price reaches USD.

If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Peter Lynch
Track and Analyze Performance

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.

Continuous Learning and Adaptation

Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.

Boost Decision Confidence

With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.

Why create notes?
Close
Back
Delete Note

Do you really want to delete this note?
This action cannot be undone.

Delete
Cancel
AMYT Alert
Amryt Pharma Holdings Ltd
143
-19 (-11.73%)
52 Week Range
N/A
N/A
Price Target

We'll email you a reminder when the closing price reaches GBX.

Save Alert

Choose the stock you wish to monitor with a price alert.

Johnson & Johnson
NYSE:JNJ
US
Berkshire Hathaway Inc
NYSE:BRK.A
US
Bank of America Corp
NYSE:BAC
US
Mastercard Inc
NYSE:MA
US
UnitedHealth Group Inc
NYSE:UNH
US
Exxon Mobil Corp
NYSE:XOM
US
Pfizer Inc
NYSE:PFE
US
Palantir Technologies Inc
NYSE:PLTR
US
Nike Inc
NYSE:NKE
US
Visa Inc
NYSE:V
US
Alibaba Group Holding Ltd
NYSE:BABA
CN
JPMorgan Chase & Co
NYSE:JPM
US
Coca-Cola Co
NYSE:KO
US
Walmart Inc
NYSE:WMT
US
Verizon Communications Inc
NYSE:VZ
US
Chevron Corp
NYSE:CVX
US
Delete Alert

This alert will be permanently deleted.

Delete
Cancel
Ask me anything about
Amryt Pharma Holdings Ltd

What unique competitive advantages
does Amryt Pharma Holdings Ltd hold over its rivals?

What risks and challenges
does Amryt Pharma Holdings Ltd face in the near future?

Provide an overview of the primary business activities
of Amryt Pharma Holdings Ltd.

Show me price targets
for Amryt Pharma Holdings Ltd made by professional analysts.

Provide an overview of the primary business activities
of Amryt Pharma Holdings Ltd.

What unique competitive advantages
does Amryt Pharma Holdings Ltd hold over its rivals?

What risks and challenges
does Amryt Pharma Holdings Ltd face in the near future?

Show all valuation multiples
for Amryt Pharma Holdings Ltd.

Provide P/S
for Amryt Pharma Holdings Ltd.

Provide P/E
for Amryt Pharma Holdings Ltd.

Provide P/OCF
for Amryt Pharma Holdings Ltd.

Provide P/FCFE
for Amryt Pharma Holdings Ltd.

Provide P/B
for Amryt Pharma Holdings Ltd.

Provide EV/S
for Amryt Pharma Holdings Ltd.

Provide EV/GP
for Amryt Pharma Holdings Ltd.

Provide EV/EBITDA
for Amryt Pharma Holdings Ltd.

Provide EV/EBIT
for Amryt Pharma Holdings Ltd.

Provide EV/OCF
for Amryt Pharma Holdings Ltd.

Provide EV/FCFF
for Amryt Pharma Holdings Ltd.

Provide EV/IC
for Amryt Pharma Holdings Ltd.

Show me price targets
for Amryt Pharma Holdings Ltd made by professional analysts.

What are the Revenue projections
for Amryt Pharma Holdings Ltd?

How accurate were the past Revenue estimates
for Amryt Pharma Holdings Ltd?

What are the Net Income projections
for Amryt Pharma Holdings Ltd?

How accurate were the past Net Income estimates
for Amryt Pharma Holdings Ltd?

What are the EPS projections
for Amryt Pharma Holdings Ltd?

How accurate were the past EPS estimates
for Amryt Pharma Holdings Ltd?

What are the EBIT projections
for Amryt Pharma Holdings Ltd?

How accurate were the past EBIT estimates
for Amryt Pharma Holdings Ltd?

Compare the revenue forecasts
for Amryt Pharma Holdings Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Amryt Pharma Holdings Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Amryt Pharma Holdings Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Amryt Pharma Holdings Ltd compared to its peers.

Compare the P/E ratios
of Amryt Pharma Holdings Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Amryt Pharma Holdings Ltd with its peers.

Analyze the financial leverage
of Amryt Pharma Holdings Ltd compared to its main competitors.

Show all profitability ratios
for Amryt Pharma Holdings Ltd.

Provide ROE
for Amryt Pharma Holdings Ltd.

Provide ROA
for Amryt Pharma Holdings Ltd.

Provide ROIC
for Amryt Pharma Holdings Ltd.

Provide ROCE
for Amryt Pharma Holdings Ltd.

Provide Gross Margin
for Amryt Pharma Holdings Ltd.

Provide Operating Margin
for Amryt Pharma Holdings Ltd.

Provide Net Margin
for Amryt Pharma Holdings Ltd.

Provide FCF Margin
for Amryt Pharma Holdings Ltd.

Show all solvency ratios
for Amryt Pharma Holdings Ltd.

Provide D/E Ratio
for Amryt Pharma Holdings Ltd.

Provide D/A Ratio
for Amryt Pharma Holdings Ltd.

Provide Interest Coverage Ratio
for Amryt Pharma Holdings Ltd.

Provide Altman Z-Score Ratio
for Amryt Pharma Holdings Ltd.

Provide Quick Ratio
for Amryt Pharma Holdings Ltd.

Provide Current Ratio
for Amryt Pharma Holdings Ltd.

Provide Cash Ratio
for Amryt Pharma Holdings Ltd.

What is the historical Revenue growth
over the last 5 years for Amryt Pharma Holdings Ltd?

What is the historical Net Income growth
over the last 5 years for Amryt Pharma Holdings Ltd?

What is the current Free Cash Flow
of Amryt Pharma Holdings Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Amryt Pharma Holdings Ltd.

Popular Prompts Strategic Analysis Valuation Future Outlook Peer Analysis Profitability Solvency Financials
Relative ValueValuation MultiplesMultiples Across CompetitorsSee Also
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

AMYT price has not been updated for more than 1 year. This may indicate that the stock has been delisted.

There is not enough data to reliably calculate the relative value of AMYT.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Valuation FAQ:
What is Relative Valuation?
How is Relative Value calculated?
AMYT Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

2.9
P/S
P/S
Price to Sales
2.9
vs History
vs Industry
Median 3Y
0
Median 5Y
2.7
Industry
2.5
Forward
0
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-0
Median 5Y
-6.5
Industry
21.8
Forward
1.8
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-0
Median 5Y
-6.7
Industry
16.6
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-0
Median 5Y
-5.7
Industry
24
More Details
2
P/B
P/B
Price to Book Value
2
vs History
vs Industry
Median 3Y
0
Median 5Y
1.9
Industry
2.1
More Details
39.8
EV/S
EV/S
Enterprise Value to Sales
39.8
vs History
vs Industry
Median 3Y
0.5
Median 5Y
39.6
Industry
2.7
Forward
0.4
More Details
80.8
EV/GP
EV/GP
Enterprise Value to Gross Profit
80.8
vs History
vs Industry
Median 3Y
0.8
Median 5Y
80.4
Industry
5.3
More Details
362.9
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
362.9
vs History
vs Industry
Median 3Y
-0.5
Median 5Y
360.7
Industry
12.8
Forward
2.7
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-2.1
Median 5Y
-355.9
Industry
16.2
Forward
16.5
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-1
Median 5Y
-96.6
Industry
15.1
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-1
Median 5Y
-93.4
Industry
17.7
More Details
11.4
EV/IC
EV/IC
Enterprise Value to IC
11.4
vs History
vs Industry
Median 3Y
0.2
Median 5Y
11.4
Industry
1.9
More Details

Multiples Across Competitors

AMYT Competitors Multiples
Amryt Pharma Holdings Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries United States of America United Kingdom Canada New Zealand Germany Bermuda Ireland Luxembourg Austria Italy France Belgium Netherlands Portugal Switzerland Spain Lithuania Estonia Latvia Finland Iceland Sweden Norway Denmark Israel Hong Kong Korea Poland Hungary Philippines Singapore India Japan Pakistan Australia Chile Saudi Arabia Thailand China Indonesia Greece South Africa Vietnam Malaysia Brazil Argentina Mexico Croatia Turkey Taiwan Peru Russia Cyprus Cayman Islands Papua New Guinea Mongolia Guernsey British Virgin Islands Panama Puerto Rico Monaco Colombia Uruguay United Arab Emirates Macao Egypt Bahamas Jersey Anguilla Nicaragua Isle of Man Mauritius Guam Venezuela Czech Republic Malta Liechtenstein Georgia Cambodia Azerbaijan Ukraine French Guiana Martinique Costa Rica Gibraltar Morocco Virgin Islands (U.S.) Faroe Islands Nigeria Bulgaria Slovenia Slovakia Romania Kazakhstan Jordan Kenya Zimbabwe Malawi
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
Amryt Pharma Holdings Ltd
LSE:AMYT
453.2m GBP 2.9 -7.1 362.9 -358.1
US
Eli Lilly and Co
NYSE:LLY
739.9B USD 15.1 66.6 35.8 39.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
375.3B USD 4.2 17.2 12.6 16.5
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.6 19.1 13.3 15.2
CH
Roche Holding AG
SIX:ROG
206.8B CHF 3.4 25 9.4 11
CH
Novartis AG
SIX:NOVN
192.2B CHF 4.5 18.8 11.1 14.8
UK
AstraZeneca PLC
LSE:AZN
160.3B GBP 4 28.2 130.8 197.2
US
Merck & Co Inc
NYSE:MRK
203.6B USD 3.2 11.7 8.7 10.5
IE
E
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
144.3B USD 2.3 18.3 7.8 10.9
P/S Multiple
Revenue Growth P/S to Growth
UK
Amryt Pharma Holdings Ltd
LSE:AMYT
Average P/S: 63.2
2.9
30%
0.1
US
Eli Lilly and Co
NYSE:LLY
15.1
23%
0.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
9%
64.3
US
Johnson & Johnson
NYSE:JNJ
4.2
4%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
6.6
15%
0.4
CH
Roche Holding AG
SIX:ROG
3.4
4%
0.9
CH
Novartis AG
SIX:NOVN
4.5
4%
1.1
UK
AstraZeneca PLC
LSE:AZN
4
7%
0.6
US
Merck & Co Inc
NYSE:MRK
3.2
5%
0.6
IE
E
Endo International PLC
LSE:0Y5F
70.5
N/A N/A
US
Pfizer Inc
NYSE:PFE
2.3
-1%
N/A
P/E Multiple
Earnings Growth PEG
UK
Amryt Pharma Holdings Ltd
LSE:AMYT
Average P/E: 25.6
Negative Multiple: -7.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
66.6
49%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.2
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.1
18%
1.1
CH
Roche Holding AG
SIX:ROG
25
32%
0.8
CH
Novartis AG
SIX:NOVN
18.8
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
28.2
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.7
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
18.3
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
UK
Amryt Pharma Holdings Ltd
LSE:AMYT
Average EV/EBITDA: 427.3
362.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.8
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.6
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
13.3
13%
1
CH
Roche Holding AG
SIX:ROG
9.4
5%
1.9
CH
Novartis AG
SIX:NOVN
11.1
5%
2.2
UK
AstraZeneca PLC
LSE:AZN
130.8
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.7
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.8
2%
3.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
UK
Amryt Pharma Holdings Ltd
LSE:AMYT
Average EV/EBIT: 1 867.3
Negative Multiple: -358.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.1
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.5
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
15.2
14%
1.1
CH
Roche Holding AG
SIX:ROG
11
6%
1.8
CH
Novartis AG
SIX:NOVN
14.8
10%
1.5
UK
AstraZeneca PLC
LSE:AZN
197.2
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.5
11%
1
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.9
10%
1.1

See Also

Summary
AMYT intrinsic value, competitors valuation, and company profile.
DCF Valuation
AMYT stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AMYT stock valuation using valuation multiples.
Wall Street Estimates
AMYT price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AMYT stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 265,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

What is relative valuation?

Relative valuation is used to value companies by comparing them to other businesses based on certain metrics such as EV/Revenue, EV/EBITDA, and P/E ratios.

Relative valuation is one of two methods of placing a monetary value on a company; the other is Discounted Cash Flow valuation method. We use a combination of these two methods to calculate the Intrinsic Value of stock as accurately as possible.

Read more
Close
How is Relative Value calculated?

Our algorithm takes into account all the information about the company's valuation multiples (their historical values, how competitors are priced, and much more) and consolidates it into one single number - relative value.

Read more
Close
Alpha Spread
Become a more intelligent investor
Sign up with Google
OR
Sign up with email
Already have an account? Sign in
By using Alpha Spread you are agreeing to our
Terms of Service and Privacy Policy.
Sign In
Become a more intelligent investor
Sign in with Google
OR
Sign in with email
Not a member? Sign Up
By using Alpha Spread you are agreeing to our
Terms of Service and Privacy Policy.
Recently Viewed Most Popular Most Undervalued Wide Economic Moat High Profitability High Solvency
Amryt Pharma Holdings Ltd
LSE:AMYT
143 GBX
-11.73%
W
Wartsila Oyj Abp
OMXH:WRT1V
19.915 EUR
-0.92%
Floor & Decor Holdings Inc
NYSE:FND
82.07 USD
-0.81%
Diversified Healthcare Trust
NASDAQ:DHC
3.75 USD
1.08%

Companies most frequently analyzed and tracked by Alpha Spread users.

Johnson & Johnson
NYSE:JNJ
156.01 USD
0.29%
Berkshire Hathaway Inc
NYSE:BRK.A
727 455 USD
0.97%
Bank of America Corp
NYSE:BAC
48.93 USD
0.45%
Mastercard Inc
NYSE:MA
569.24 USD
1.37%
UnitedHealth Group Inc
NYSE:UNH
308.55 USD
0.32%
Exxon Mobil Corp
NYSE:XOM
112.2 USD
1.04%
View Most Popular Stocks Full List

Every business has a fair value, its true price. Where market price tells you the price other people are willing to pay, fair value shows the value of a stock based on an analysis of the company’s actual financials (such as cash balance, revenue, operating margin, etc).

Franklin Covey Co
NYSE:FC
22.1 USD
-8.56%
Mohawk Industries Inc
NYSE:MHK
110.84 USD
-0.4%
Ardmore Shipping Corp
NYSE:ASC
10.25 USD
0.49%
ASGN Inc
NYSE:ASGN
52.84 USD
1.23%
Skyworks Solutions Inc
NASDAQ:SWKS
78.76 USD
0.74%
Weatherford International PLC
NASDAQ:WFRD
54.15 USD
-2.11%
View Most Undervalued Stocks Full List

Economic Moat is a concept popularized by Warren Buffett to describe a company's durable competitive advantage. It represents the 'moat' that protects a company from competitors and helps it sustain profitability over the long term.

Johnson & Johnson
NYSE:JNJ
156.01 USD
0.29%
Bank of America Corp
NYSE:BAC
48.93 USD
0.45%
Mastercard Inc
NYSE:MA
569.24 USD
1.37%
Salesforce Inc
NYSE:CRM
272.15 USD
1.09%
Abbvie Inc
NYSE:ABBV
189.28 USD
-0.77%
Home Depot Inc
NYSE:HD
371.68 USD
-0.05%
View Wide Economic Moat Stocks Full List

Companies demonstrating exceptional profitability and efficient operations.

Arista Networks Inc
NYSE:ANET
102.52 USD
1.37%
Deckers Outdoor Corp
NYSE:DECK
106.2 USD
-0.06%
Visa Inc
NYSE:V
358.86 USD
1.31%
Texas Pacific Land Corp
NYSE:TPL
1 075.97 USD
0.38%
KLA Corp
NASDAQ:KLAC
924.58 USD
0.38%
Manhattan Associates Inc
NASDAQ:MANH
199.93 USD
0.61%
View High Profitability Stocks Full List

Companies with the lowest probability of bankruptcy.

Salesforce Inc
NYSE:CRM
272.15 USD
1.09%
Accenture PLC
NYSE:ACN
304.78 USD
0.82%
ServiceNow Inc
NYSE:NOW
1 044.69 USD
3.46%
Spotify Technology SA
NYSE:SPOT
725.05 USD
2.19%
EOG Resources Inc
NYSE:EOG
123.15 USD
0.22%
Applied Materials Inc
NASDAQ:AMAT
191.05 USD
0.55%
View High Solvency Stocks Full List
Stock Screener
Discover stocks tailored to your investment strategy.
Open Stock Screener
You don't have any saved screeners yet
Other Tools
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF
Discount Rate Calculator
Cost of Equity & WACC

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett
Warning
AMYT is delisted

This means that the stock is removed from a stock exchange and can no longer be traded.

Delisting typically occurs when a stock no longer meets exchange requirements. Other reasons for delisting may include legal violations, bankruptcy, a decrease in the number of shareholders, and acquisition by another company.

Close
Create Your Free Account
Already have an account? Sign in
Gain access to the world’s leading value investing platform
Gain access to the world’s leading value investing platform

By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.

Sign up with Google
OR
Create Free Account

By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.